|
Synonyms: OMP-21M18 | OMP21M18
Compound class:
Antibody
Comment: Demcizumab is a humanised IgG2 monoclonal antibody targeting DLL4 (delta like canonical Notch ligand 4), a membrane bound Notch receptor ligand expressed predominantly on vascular endothelial cells.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. A BLAST search using the peptide sequence of the variable region of the heavy chain forming demcizumab reveals US7750124 B2 as the covering patent [2]. |
| No information available. |
Summary of Clinical Use  |
| Demcizumab was advanced to clinical trials in patients with advanced solid tumours (max phase 2). However, development appears to have been discontinued. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Epitope mapping reveals that demcizumab binds to an epitope within the DSL domain (Delta/Serrate/lag-2) of DLL4 [2]. Demcizumab binds to DLL4 (delta like canonical Notch ligand 4) and prevents this ligand from activating receptors of the Notch signalling pathway. Notch pathway inhibition has anti-cancer effects. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02259582 | A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | Phase 2 Interventional | Mereo BioPharma | 3 | |
| NCT00001693 | Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers | Phase 1 Interventional | National Institutes of Health Clinical Center (CC) | 1 | |
